A webinar, organized by the Global Vaccine and Immunization Research Forum (GVIRF), brought together experts to discuss the status of TB vaccine development across the value chain, from articulation of the public health and economic need for new TB vaccines through the status and strategies for product development, to the considerations for approval, policy recommendation and use.

• Studying the safety, immunogenicity and efficacy of MTBVAC in the most populated country in the world and the one with the highest number of cases of this infectious disease is key to continue advancing in this vaccine.

• Bharat Biotech International Limited in collaboration with Biofabri have started a series of clinical trials to evaluate the safety, immunogenicity and efficacy of MTBVAC in India.

• MTBVAC is being developed for two purposes: as a more effective and potentially longer-lasting vaccine than BCG for newborns, and for the prevention of TB disease in adults and adolescents, for whom there is currently no effective vaccine.

Spain. 24 March 2024. MTBVAC, the Spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, reaches a new milestone by starting clinical trials in India, the most populated country in the world and the one with the highest number of cases of this infectious disease. 

The TB Vax ARM outlines three key advocacy wins for the field to achieve by 2026 in order to effectively advance TB vaccine development. Check them out and sign a petition to show your support!

-- A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis
-- Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries
-- The M72/AS01E vaccine candidate could be the first new TB vaccine in 100 years if proven effective

Treatment Action Group (TAG) released an overview of TB research data reported at the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held on 3-6 March 2024 in Denver, Colorado, USA.

The Office of HIV/AIDS Network Coordination (HANC) and the TB Trials Consortium Community Research Advisors Group hosted a webinar on 22 February 2024 focused on TB vaccines.

The Stop TB Partnership Working Group on New TB Vaccines (WGNV) released a newsletter with the latest updates related to TB vaccines.

There are many reasons why HIV is such a perplexing virus to combat. One of them is that there are incredibly few people — only a few, if that, of the nearly 86 million people to acquire HIV to date — who have naturally cleared the virus after becoming infected. Once an HIV infection occurs, it almost always persists in the body for a lifetime.

The Office of HIV/AIDS Network Coordination (HANC) and the TB Trials Consortium Community Research Advisors Group will host a webinar on 22 February 2024 focused on TB vaccines.